Market participants now increasingly focus their development efforts on the newly discovered role that CoQ10 plays in cellular energy production, healthy vision, migraine relief and infertility treatment. This emphasis on new health profiles and applications will help industry players expand
Developed by MedImmune (now wholly owned by AstraZeneca), motavizumab is an investigational monoclonal antibody (MAb) indicated for the prevention of respiratory syncytial virus (RSV) infection in high-risk infants.Following the successful outcome of large-scale phase III paediatric clinical trials, a Biologics
Genentech is one of the most successful biotech companies on a world scale with four drugs prominent on the commercial market and around 50 drugs in its pipeline. The company is headquartered in South San Francisco, US, and has one
OroCell is a spheronised mannitol compound with outstanding characteristics as a binder, filler and carrier in immediate release oral dispersible tablet (ODT) preparations. OroCell has exceptional processing features as a result of innovative spheronisation technologies.In addition it can be used
Oncolytics Biotech has started patient enrollment in a Phase II clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.
SpePharm Holding has announced the granting of national approvals of Loramyc in the UK, Denmark, Germany, Belgium, The Netherlands, Luxembourg, Finland and Sweden, as well as in Spain under the trade name Sitamic.
Prospect Therapeutics has reported positive interim results from the ongoing Phase II trial on its product candidate GCS-100 for the treatment of chronic lymphocytic leukemia.
Access Pharmaceuticals and Jiangsu Aosaikang Pharmaceutical have signed a definitive licensing agreement under which ASK will manufacture, develop and commercialize Access's product ProLindac for the Greater China Region which includes the People's Republic of China, the Hong Kong Special Administrative
Lev Pharmaceuticals has entered into multi-year agreements with CuraScript, CVS Caremark and FFF Enterprises to serve as its specialty pharmacy, specialty distribution and patient services partners to support the US commercialization of Cinryze, an investigational treatment for hereditary angioedema, also
Bioject Medical Technologies and ImmunoVaccine Technologies have entered into a collaborative research agreement to assess utilization of the Biojector 2000 for the delivery of ImmunoVaccine's vaccine enhancement platform, DepoVax.
Laboratory Corporation of America Holdings and Vanda Pharmaceuticals have announced an exclusive alliance to develop and commercialize a series of diagnostic tests for genetic markers identified by Vanda in the course of its clinical development of Fanapta, an atypical antipsychotic
Generex Biotechnology has commenced dosing of patients in a Phase III clinical trial of the company's flagship product, Generex Oral-lyn, an oral insulin spray.
Emergent BioSolutions has announced that dosing of patients has begun in a US Phase II clinical trial of the company's single-dose oral typhoid vaccine candidate.
InteKrin Therapeutics has reported positive data from a Phase IIa study with INT131, a non-TZD selective peroxisome proliferator-activated receptor modulator, in patients with Type 2 diabetes mellitus.
MedSpas of America has updated its worldwide supply agreement with Zymetech from Reykjavick, Iceland, for the use of Penzim as the essential ingredient in the anti-aging line of products for Natural Renu.
Rosetta Genomics has announced a research collaboration with The University of Texas MD Anderson Cancer Center and the Kleberg Center for Molecular Markers to develop a microRNA-based diagnostic test to predict risk of disease recurrence in lung cancer patients who
Genta has submitted an amendment to the FDA for its new drug application for Genasense injection plus chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia.
Cytori Therapeutics and Green Hospital Supply have expanded the StemSource cell bank commercialization partnership to include Korea, Taiwan and Thailand.
Roxane Laboratories has announced the approval of its abbreviated new drug application for Zaleplon capsules CIV, 5mg and 10mg, a sedative/hypnotic, mainly used for insomnia.
Del Global Technologies has announced that Del Medical Systems Group has signed a two-year supply agreement with Pinnacle Management Group for its DCChoice product line.
